search
Back to results

Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults

Primary Purpose

Obesity

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
topiramate
phentermine
topiramate
phentermine
Sponsored by
VIVUS LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Obesity

Eligibility Criteria

19 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Obese adults
  • Body mass index between 30.0 and 42.0 kg/m2 (inclusive)
  • Medically healthy with no clinically significant results of screening exams

Exclusion Criteria:

  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
  • History of glaucoma or increased intraocular pressure
  • History of kidney stones
  • Cholelithiasis or cholecystitis within 6 months
  • Cardiovascular event within 6 months
  • Obesity of known genetic or endocrine origin
  • Recent weight instability
  • Use of Very Low Calorie diet or participation in organized weight loss program within 3 months
  • Systolic blood pressure > 150 or diastolic > 95 mm Hg
  • Positive urine drug or alcohol screen
  • Positive serology for HIV, HBV, or HCV
  • History of alcoholism or drug abuse
  • History of significant psychiatric disease, current depression of moderate or greater severity, any history of suicidal ideation
  • Hypersensitivity to study drug or related compounds
  • Use of prescription or OTC medication other than hormonal contraceptive within 14 days prior to first dosing with study drug
  • Blood donation or significant blood loss within 56 days or plasma donation within 7 days prior to first dosing with study drug
  • Women who are pregnant or lactating
  • Hemoglobin < 12 g/dL
  • Use of tobacco or nicotine-containing products within 6 months

Sites / Locations

  • VIVUS, Inc.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

treatment 1

treatment 2

treatment 3

treatment 4

Arm Description

One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1. One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2. One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Days 4 - 21 of Period 2.

Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1. One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2. One 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsules at Hour 0 on Days 4, 5, and 6 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules (Cardinal) and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2.

Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1. One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsule at Hour 0 on Days 4, 5, and 6 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2.

Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Day 1 of Period 1. One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate IR tablet at Hour 0 on Days 1, 2, and 3 of Period 2. Half of a 37.5 mg phentermine hydrochloride IR tablet and two 25 mg topiramate IR tablets at Hour 0 on Days 4, 5, and 6 of Period 2. Half of a 37.5 mg phentermine hydrochloride IR tablet and three 25 mg topiramate IR tablets at Hour 0 on Days 7, 8, and 9 of Period 2. Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Days 10 - 21 of Period 2.

Outcomes

Primary Outcome Measures

Pharmacokinetic parameters

Secondary Outcome Measures

Full Information

First Posted
August 16, 2007
Last Updated
June 6, 2011
Sponsor
VIVUS LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00518466
Brief Title
Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults
Official Title
A Phase Ib, Open Label, Parallel-Design Single- and Multiple-Dose Study Comparing Modified Release Topiramate Formulations to Immediate Release Formulations of Topiramate Dosed in Combination With Immediate Release Phentermine in Obese Adults
Study Type
Interventional

2. Study Status

Record Verification Date
June 2011
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
September 2007 (Actual)
Study Completion Date
December 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
VIVUS LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
64 (Actual)

8. Arms, Groups, and Interventions

Arm Title
treatment 1
Arm Type
Experimental
Arm Description
One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1. One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2. One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Days 4 - 21 of Period 2.
Arm Title
treatment 2
Arm Type
Experimental
Arm Description
Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1. One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2. One 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsules at Hour 0 on Days 4, 5, and 6 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules (Cardinal) and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2.
Arm Title
treatment 3
Arm Type
Experimental
Arm Description
Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1. One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsule at Hour 0 on Days 4, 5, and 6 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2.
Arm Title
treatment 4
Arm Type
Experimental
Arm Description
Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Day 1 of Period 1. One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate IR tablet at Hour 0 on Days 1, 2, and 3 of Period 2. Half of a 37.5 mg phentermine hydrochloride IR tablet and two 25 mg topiramate IR tablets at Hour 0 on Days 4, 5, and 6 of Period 2. Half of a 37.5 mg phentermine hydrochloride IR tablet and three 25 mg topiramate IR tablets at Hour 0 on Days 7, 8, and 9 of Period 2. Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Days 10 - 21 of Period 2.
Intervention Type
Drug
Intervention Name(s)
topiramate
Intervention Description
25 mg modified-release capsules
Intervention Type
Drug
Intervention Name(s)
phentermine
Intervention Description
7.5 mg immediate-release capsules
Intervention Type
Drug
Intervention Name(s)
topiramate
Intervention Description
100 and 25 mg immediate-release tablets
Intervention Type
Drug
Intervention Name(s)
phentermine
Intervention Description
37.5 and 7.5 mg immediate-release tablets
Primary Outcome Measure Information:
Title
Pharmacokinetic parameters
Time Frame
One month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Obese adults Body mass index between 30.0 and 42.0 kg/m2 (inclusive) Medically healthy with no clinically significant results of screening exams Exclusion Criteria: History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease History of glaucoma or increased intraocular pressure History of kidney stones Cholelithiasis or cholecystitis within 6 months Cardiovascular event within 6 months Obesity of known genetic or endocrine origin Recent weight instability Use of Very Low Calorie diet or participation in organized weight loss program within 3 months Systolic blood pressure > 150 or diastolic > 95 mm Hg Positive urine drug or alcohol screen Positive serology for HIV, HBV, or HCV History of alcoholism or drug abuse History of significant psychiatric disease, current depression of moderate or greater severity, any history of suicidal ideation Hypersensitivity to study drug or related compounds Use of prescription or OTC medication other than hormonal contraceptive within 14 days prior to first dosing with study drug Blood donation or significant blood loss within 56 days or plasma donation within 7 days prior to first dosing with study drug Women who are pregnant or lactating Hemoglobin < 12 g/dL Use of tobacco or nicotine-containing products within 6 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wesley W Day, PhD
Organizational Affiliation
VIVUS LLC
Official's Role
Study Director
Facility Information:
Facility Name
VIVUS, Inc.
City
Mountain View
State/Province
California
ZIP/Postal Code
94040
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults

We'll reach out to this number within 24 hrs